A radiation-controlled molecular switch for use in gene therapy of cancer.
Authors
Scott, S DMarples, B
Hendry, Jolyon H
Lashford, Linda S
Embleton, M J
Hunter, Robin D
Howell, Anthony
Margison, Geoffrey P
Affiliation
Cancer Research Campaign Section of Genome Damage and Repair, Paterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester, UK.Issue Date
2000-07
Metadata
Show full item recordAbstract
Ionising radiation induces the expression of a number of radiation-responsive genes and there is current interest in exploiting this to regulate the expression of exogenous therapeutic genes in gene therapy strategies for cancer. However, the radiation-responsive promoters used in these approaches are often associated with low and transient levels of therapeutic gene expression. We describe here a novel radiation-triggered molecular switching device based on promoter elements from the radiation-responsive Egr-1 gene and the cre-LoxP site-specific recombination system of the P1 bacteriophage. Using this system, a single, minimally toxic dose of radiation induced cre-mediated excision of a lox-P flanked stop cassette in a silenced expression vector and this resulted in amplified levels of CMV-promoter-driven expression of the exogenous tumour-sensitising gene, HSV-tk. This strategy could be used in combination with targeted delivery and tumour-specific promoters to elicit the tumour-targeted and prolonged expression of a variety of tumour-sensitising genes and provide an unprecedented level of control and tumour selectivity.Citation
A radiation-controlled molecular switch for use in gene therapy of cancer. 2000, 7 (13):1121-5 Gene Ther.Journal
Gene TherapyPubMed ID
10918478Type
ArticleLanguage
enISSN
0969-7128Related articles
- Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity.
- Authors: Cheon J, Kim HK, Moon DG, Yoon DK, Cho JH, Koh SK
- Issue date: 2000 Apr
- Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer.
- Authors: Kijima T, Osaki T, Nishino K, Kumagai T, Funakoshi T, Goto H, Tachibana I, Tanio Y, Kishimoto T
- Issue date: 1999 Oct 1
- Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation.
- Authors: Kawashita Y, Ohtsuru A, Kaneda Y, Nagayama Y, Kawazoe Y, Eguchi S, Kuroda H, Fujioka H, Ito M, Kanematsu T, Yamashita S
- Issue date: 1999 Jun 10
- Gene therapy utilizing the Cre/loxP system selectively suppresses tumor growth of disseminated carcinoembryonic antigen-producing cancer cells.
- Authors: Goto H, Osaki T, Kijima T, Nishino K, Kumagai T, Funakoshi T, Kimura H, Takeda Y, Yoneda T, Tachibana I, Hayashi S
- Issue date: 2001 Nov 1
- Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
- Authors: Greco O, Joiner MC, Doleh A, Powell AD, Hillman GG, Scott SD
- Issue date: 2006 Feb